A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Pacific6 Enterprises and JM Molina Investments Announce a Joint Investment in Detact Diagnostics

December 18, 2020

Pacific6 Enterprises and JM Molina Investments, today announced a joint investment to acquire a 33% interest in Detact Diagnostics™, a Netherlands-based life-science company.

Pacific6 is an investment partnership founded, in part, by John Molina, the former CFO of Molina Healthcare. His brother, J. Mario Molina, M.D., former CEO of Molina Healthcare, is the principal behind JM Molina Investments.

Detact Diagnostics™, founded in 2014 by former trauma surgeon Joost Gazendam, specializes in the development of bacterial and viral detection technologies. The company’s innovative, patented technique can accurately and reliably detect the presence of a bacteria or virus within minutes. This proprietary detection platform – uniquely suited to developing quick, affordable, point of care tests – serves as the foundation for the company’s current development of a rapid Covid-19 screening test, CoviTact©.

The novel CoviTact© saliva screening test is low-cost and requires no laboratory processing nor trained clinical staff to administer, and yields results in under two minutes – making it ideal for strategic deployment at venues worldwide.

“Joost and his team have been laser-focused on creating an innovative, disruptive diagnostic technology,” said John Molina, Founding Partner at Pacific6. “This investment will extend our company’s international reach and help accelerate the development of affordable, reliable testing technologies that will dramatically change the rapid-test landscape.”

“We couldn’t be more enthusiastic to partner with the Molinas,” said Dr. Joost Gazendam, CEO of Detact Diagnostics. “They share our vision for healthy living and we’re excited to have a partner that not only provides funding but also brings a vast amount of experience as a leader in the healthcare industry.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

By using this website you agree to accept Medical Device News Magazine Privacy Policy